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Objective: This study was conducted to evaluate the efﬁcacy and safety of pegylated liposo-
mal doxorubicin (PLD) in Japanese patients with Mu ¨llerian carcinoma having a therapeutic
history of platinum-based chemotherapy.
Methods: Patients who were diagnosed with Mu ¨llerian carcinoma (epithelial ovarian
carcinoma, primary carcinoma of fallopian tube and peritoneal carcinoma) by histological
examination and had received the initial platinum-based chemotherapy were included in the
study. The study drug was administered to the patients at 50 mg/m
2 every 4 weeks.
Results: Seventy-four patients were enrolled in the study. All patients had received platinum-
based chemotherapy as ﬁrst-line regimen and more than 90% of patients had also received
taxanes. The overall response rate was 21.9% (95% conﬁdence interval, 13.1–33.1%) and
38.4% of patients had stable disease. The median time to progression was 166 days. The
major non-haematological toxicities were hand-foot syndrome (Grade 3; 16.2%) and stomati-
tis (Grade 3; 8.1%). Myelosuppression such as leukopenia (Grade 3; 52.7%, Grade 4; 6.8%),
neutropenia (Grade 3; 31.1%, Grade 4; 36.5%) and decreased haemoglobin (Grade 3;
14.9%, Grade 4; 2.7%) were the most common haematological toxicities.
Conclusion: We conﬁrmed that a 50 mg/m
2 every 4 weeks regimen of PLD was active
in Japanese patients with Mu ¨llerian carcinoma having a therapeutic history of platinum-
based chemotherapy and toxicity was manageable by dose modiﬁcation of PLD or supportive
care.
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INTRODUCTION
Approximately 8000 cases of ovarian cancer are newly diag-
nosed in Japan and more than 4000 women die of this disease
(1). From an embryologic perspective, epithelial ovarian
carcinoma, primary carcinoma of fallopian tube and peritoneal
carcinoma are generally recognized as a similar disease group,
which is known as Mu ¨llerian carcinoma. In patients with
primary carcinoma of the fallopian tube and peritoneal carci-
noma, the experience with chemotherapeutic agents is largely
limited to case reports and small studies due to the rarity of
disease type (2,3). However, the overall experience closely
parallels that of ovarian cancer, so treatment of primary
carcinoma of the fallopian tube and peritoneal carcinoma is
conducted according to that of ovarian cancer (2,3).
Advanced epithelial ovarian cancer is a highly chemo-
sensitive solid tumour with response rates to ﬁrst-line
chemotherapy of  80%. The majority of patients, however,
eventually relapse and treatment with second-line agents
becomes necessary. Furthermore, patients with recurrent
ovarian cancer ultimately die of chemoresistant disease.
Therefore, it is very important to recognize recurrent ovarian
cancer therapy as palliative therapy and therapeutic agents
are required to show efﬁcacy as well as favourable toxicity
proﬁle. However, there are not many drugs approved in Japan
for ovarian carcinoma, or recommended by the Japanese
clinical practice guideline for as second-line treatment except
platinum, taxane and irinotecan.
Pegylated liposomal doxorubicin (PLD) is a formulation
of doxorubicin hydrochloride encapsulated in long circulat-
ing STEALTH
w liposomes and formulated for intravenous
administration. STEALTH
w liposomes have liquid mem-
branes coated with polyethylene glycol, which attracts water
and renders resistance to mononuclear phagocytosis (4). The
liposome’s small diameter ( 100 nm) and their persistence
in the circulation allow their penetration into altered and
often compromised, leaky tumour vasculature with entry into
the interstitial space in malignant tissues (5). Therefore,
pegylated liposomes are suitable for prolonged delivery of
doxorubicin and have a prolonged circulation time (6,7). At
these tumour sites, the accumulating liposomes gradually
break down, releasing doxorubicin to the surrounding
tumour cells (8,9). PLD has been designed to enhance the
efﬁcacy and to reduce the toxicities of doxorubicin such as
myelosuppression, alopecia and cardiotoxicity by altering
the plasma pharmacokinetics and tissue distribution of the
drug.
Based on the data from the Phases II and III clinical trials
in Europe and the USA, it is evident that PLD possesses
promising activity and a favourable toxicity proﬁle in the
second-line treatment of ovarian cancer (10–15). Currently,
PLD is provided as one of the standard treatment options in
recurrent ovarian cancer treatment guidelines (16–18).
The result of the Phase I clinical trial in Japan was
reported (19). In that study, recommended PLD dose was
evaluated in 15 Japanese patients with solid tumours and
resulted in 50 mg/m
2 every 4 weeks. In addition, one partial
response (PR) and one normalization of CA125 were
observed among six ovarian cancer patients enrolled in that
study, and further trials with Japanese ovarian cancer
patients were encouraged.
Based on the result from a Phase I clinical trial in Japan,
we conducted the Phase II clinical trial of PLD in patients
with recurrent or relapsed Mu ¨llerian carcinoma (epithelial
ovarian carcinoma, primary carcinoma of fallopian tube,
peritoneal carcinoma) having a therapeutic history of
platinum-based chemotherapy.
We conducted a multicentre, non-randomized, open-label
study to evaluate efﬁcacy and safety of a PLD 50 mg/m
2
every 4-week regimen in Japanese patients with Mu ¨llerian
carcinoma who had previously been treated with platinum-
based chemotherapy.
PATIENT AND METHODS
STUDY DESIGN
This study was a multicentre non-randomized, open-label
trial to evaluate efﬁcacy and safety of PLD in Japanese
patients with Mu ¨llerian carcinoma previously treated with
platinum-based chemotherapy. The primary endpoint was the
best overall response (response rate) and secondary endpoints
included adverse events and adverse drug reactions (inci-
dence, severity, seriousness and causality), time to response
and duration of response. The ﬁnal evaluation of the antitu-
mour effect was performed by the independent radiological
review committee. The study protocol was approved by the
institutional review board at each site. This study was con-
ducted based on ethical principles in the Declaration of
Helsinki and in compliance with Good Clinical Practice.
PATIENTS
This study included patients who met all the following
inclusion criteria: (i) having histological conﬁrmation of
Mu ¨llerian carcinoma (epithelial ovarian carcinoma, primary
fallopian tube carcinoma and peritoneal carcinoma);
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who would receive PLD as a second-line therapy if time to
progression was within 12 months from the date of ﬁnal
administration of platinum therapy, excluding patients whose
best response to ﬁrst-line platinum-based chemotherapy was
progressive disease (PD), or who received PLD as a third-line
therapy; (iii) receiving 1 or 2 regimens with prior chemother-
apy; (iv) having measurable lesions that conformed to the
Response Evaluation Criteria in Solid Tumours (RECIST)
criteria; (v) ECOG performance status (PS) grade of 0–2;
(vi) adequate functions of principal organs, deﬁned by white
blood cell (WBC) counts 3.0   10
3–12.0  10
3/mm
3, neutro-
phil counts not less than 1.5   10
3/mm
3, haemoglobin not less
than 9.0 g/dl, platelet count not less than 10.0   10
4/mm
3,
serum AST, ALT and AP not more than 2.5 times the insti-
tutional upper limit of normal, total bilirubin not more than
the institutional upper limit of normal, serum creatinine not
more than 1.5 times the institutional upper limit of normal,
left ventricular ejection fraction (LVEF) not less than 50%,
electrocardiography (ECG) normal or minor change without
symptoms that required any therapeutic intervention, and no
evidence of cardiac disorder or Class I in New York Heart
Association (NYHA) functional classiﬁcation; (vii) no colony
stimulating factor (CSF) agent or blood transfusion received
within 2 weeks before the date of blood tests for screening;
(viii) no previous treatment with hormonal agents, oral antim-
etabolic or immunotherapeutic agents for at least 2 weeks,
with nitrosourea or mitomycin C at least 6 weeks, or with
surgical therapy, radiation therapy or other chemotherapy for 4
weeks or more; (ix) abilities to stay in hospital for 4 consecu-
tive weeks from the initial administration of PLD; (x) survival
expectancy 3 months or longer; (xi) 20–79 of age years at
enrolment in the trial; and (xii) received an explanation of this
trial from the physicians with written informed consent forms
and other relevant information and freely provided informed
consent before the trial.
Patients who met any of the following exclusion criteria
were excluded from the trial: (i) requiring drainage of peri-
cardial ﬂuid; (ii) having experienced myocardial infarction
or angina attack within 90 days before the start of trial;
(iii) receiving prior therapy with anthracycline (total anthra-
cycline dose of more than 250 mg/m
2 as doxorubicin); and
(iv) having known hypersensitivity to doxorubicin or any
component of PLD.
MEDICATION
PLD was intravenously administered to each subject at a
dose of 50 mg/m
2 as doxorubicin hydrochloride on Day 1 of
each cycle, followed by a treatment-free interval of 28 days
including Day 1. This was repeated for at least two cycles if
the subject did not meet the withdrawal criteria. PLD was
administered at a rate of 1.0 mg/min from the start of infu-
sion to completion, using an infusion pump in consideration
of risks of development of infusion-related reactions. PLD
was used by diluting with 250 ml of 5% glucose injection
for a dose of less than 90 mg as doxorubicin hydrochloride
or with 500 ml for a dose of 90 mg or more as doxorubicin
hydrochloride.
After administration, PLD would be discontinued in sub-
jects who met any of the following withdrawal criteria:
(i) desiring to discontinue the study treatment or withdrawing
consent; (ii) having LVEF decreased to less than 45% after
administration of PLD or decreased by 20% or more than
baseline; (iii) having no possibility for a subsequent cycle to
be started within 6 weeks from the planned injection date
because of adverse reactions or after 8 weeks for hand-foot
syndrome (HFS) or stomatitis; (iv) having bilirubin increased
to 3.0 mg/dl or more; (v) requiring a repeated reduction in
the dose; (vi) the anticipated total dose of anthracycline
antibiotics including PLD would exceed 500 mg/m
2 as
doxorubicin hydrochloride (including doses from prior
chemotherapy and pre/postoperative treatment); (vii) being
judged by the physician to have difﬁculties continuing the
trial due to serious (or signiﬁcant) adverse events;
(viii) being assessed to have difﬁculty continuing the trial due
to concurrent illnesses (e.g. complications); (ix) having
obvious progression of the underlying disease or development
of new lesions (PD); (x) having any of the exclusion criteria
which was discovered after enrolment; and (xi) being judged
as unfavourable to continue the trial by the physician.
Prior to administration of the study drug in the next cycle,
all the subjects were conﬁrmed to meet all the following cri-
teria: (i) HFS or stomatitis  Grade 1; (ii) neutrophil counts
 1.5   10
3/mm
3; (iii) WBC counts  3.0   10
3/mm
3;
(iv) platelet counts  7.5   10
4/mm
3; (v) bilirubin  1.5 mg/
dl; and (vi) other adverse drug reactions   Grade 2 (exclud-
ing fatigue, nausea, vomiting, anorexia, hypokalemia, hypo-
natremia and lymphopenia). If any of these criteria was not
met, the scheduled administration of the study drug for the
next cycle would be delayed for 2 weeks at the maximum. If
any of the above criteria was still not met after a 2-week
delay from the scheduled initial date of each cycle, the trial
for the subjects would be discontinued. In case Grade 2 HFS
or stomatitis was observed at 6 weeks from the initial date of
each cycle, the scheduled administration of the test drug for
the next cycle would be delayed for 2 weeks. As a result,
when the subjects met all the above criteria, the next cycle
would be started. Even if the subjects met all the criteria, the
scheduled initial date could be delayed for a maximum of 2
weeks at the investigator’s discretion.
As the subjects met any of the following dose reduction
criteria, the previous dose would be reduced by 25%
(37.5 mg/m
2) for the next cycle: (i) HFS or stomatitis  
Grade 3; (ii) neutrophil count ,500/mm
3 or WBC count
,1000/mm
3 that was maintained for at least 7 days; (iii) neu-
trophil counts ,1000/mm
3 with 38.08C or higher fever;
(iv) platelet reduction ,2.5   10
4/mm
3; (v) other adverse
drug reactions   Grade 3 (excluding fatigue, nausea, vomit-
ing, anorexia, hypokalemia, hyponatremia, lymphopenia and
other adverse events associated with infusion-related reac-
tions); and (vi) the physician judged that the dose should be
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was prohibited to increase the dose after the dose was
reduced. If a further dose reduction was required after the
dose was reduced, the trial for the subject would be
discontinued.
Administration of CSF was admitted when patients met
any of the following criteria: (i) neutrophil counts ,1000/
mm
3 with fever ( 388C); (ii) neutrophil counts ,500/mm
3;
(iii) experience of either (i) or (ii) in the prior cycle and neu-
trophil counts ,1000/mm
3 in the following cycle.
EVALUATION OF RESPONSE AND SAFETY
Tumour response evaluation was performed according to the
RECIST guidelines. Conﬁrmed duration of stable disease
(SD) was deﬁned as the duration of 8 consecutive weeks or
longer after the start of administration.
Severity of adverse events was assessed according to the
Common Terminology Criteria for Adverse Events (CTCAE)
Version 3.0.
SAMPLE SIZE AND STATISTICAL ANALYSIS
Among the subjects enrolled in this trial, those who received
platinum-based chemotherapy as the ﬁrst-line chemotherapy
and experienced disease progression between 6 and 12
months after the completion of the platinum regimen were
classiﬁed as the platinum-sensitive group, and those who had
progression during the ﬁrst-line chemotherapy, received
platinum-based chemotherapy as the ﬁrst-line chemotherapy
and experienced progression less than 6 months after the
completion of the platinum regimen, or who would receive
PLD as a third-line therapy were classiﬁed as the platinum-
resistant group. A sample size to produce the expected
response rate of 30 and 15% for the platinum-sensitive and
platinum-resistant groups, respectively, with the threshold
response rate of 5%, a signiﬁcance level of 5% and power of
80% was determined to be 80 patients in total (20 and 60
patients for the platinum-sensitive and platinum-resistant
groups, respectively).
For the response evaluation, statistical analysis was
performed based on the evaluation for the full analysis set
(FAS) by the independent radiological review committee.
The primary endpoint was the response rate, the proportion
of patients with complete response (CR) or PR in the
response analysis set, and the point estimate and two-sided
95% conﬁdence interval (CI) were calculated. The secondary
endpoints included the duration of overall response, time to
response and time to progression, and the progression-free
survival was analysed using the Kaplan–Meier method, and
descriptive statistics (median, minimum and maximum) were
calculated. The safety of PLD was evaluated for all the sub-
jects treated with PLD. Statistical analyses were performed
using the SAS System for Windows release 8.02.
RESULT
Demographics and baseline characteristics of patients are
shown in Table 1. Seventy-four patients were enrolled into
the trial between January and December 2005, and 73
patients (11 for the platinum-sensitive group and 62 for the
platinum-resistant group), excluding one patient who was
conﬁrmed to be ineligible after enrolment, were eligible for
the trial, and deﬁned as the FAS. All 74 patients who
received PLD were deﬁned as the safety analysis set.
Although the targeted number of patients for the platinum-
sensitive group was 20, only 11 patients were enrolled. That
was because the study was closed at the end of 2005 when
the patient enrolment in the platinum-resistant group reached
the target number due to slow enrolment.
The median of patients’ age was 57.0 years (range, 32–
76). Among 74 patients enrolled, 62 had epithelial ovarian
carcinoma and 12 had peritoneal carcinoma. Histological,
49 patients had serous carcinoma, eight had endometrioid
carcinoma, eight had clear cell carcinoma, one had muci-
nous carcinoma and eight had other types of carcinoma. All
74 patients had received ﬁrst-line chemotherapy including
platinum regimen, 70 (94.6%) had also received taxanes as
the ﬁrst-line chemotherapy, and only three had received
anthracycline in the prior chemotherapy. A total of 334
cycles of PLD was administered to 74 patients, and the
median number of cycles administered was 4.0 (range, 1–
10 cycles). Administration of PLD was completed or dis-
continued in all 74 patients before statistical analysis. The
dose of PLD was reduced to 37.5 mg/m
2 in 26 of 74
patients (35.1%). The scheduled administration of PLD was
d e l a y e di n4 9o f7 4p a t i e n t s( 6 6 . 2 % )a n di n1 5 4o f3 3 4
cycles (46.1%).
RESPONSE
The antitumour effect (best overall response) and response
rate are shown in Table 2. The best overall response in 73
patients of FAS was CR in two patients, PR in 14, SD in 28,
PD in 27 and not evaluable (NE) in two patients. The
response rate was 21.9% (16 of 73) (95% CI: 13.1–33.1%).
The response rate (two-sided 95% CI) by patient group was
27.3% (3 of 11) (95% CI: 6.0–61.0%) in the platinum-
sensitive group and 21.0% (13 of 62) (95% CI: 11.7–33.2%)
in the platinum-resistant group. The proportion of patients
with CR, PR or SD was 60.3% (44 of 73) in FAS, and
54.5% (6 of 11) in the platinum-sensitive group and 61.3%
(38 of 62) in the platinum-resistant group.
The results from subgroup analysis sets by platinum-free
interval were as follows. In a subgroup analysis set where
patients received PLD as a second-line therapy, the response
rate by platinum-free intervals was 8.3% (1 of 12) and
27.3% (3 of 11) in patients with the platinum-free interval of
within 6 months and of 6–12 months, respectively. In
another subgroup analysis set where patients received PLD
as a third-line therapy, the response rate was 7.1% (1 of 14),
780 Phase II study of the Japanese Gynecologic Oncology Group15.4% (2 of 13) and 36.8% (7 of 19) in patients with the
platinum-free interval of within 6 months, of 6–12 months
and more than 12 months, respectively.
The response rate by histological type was 29.2% (14 of
48) and 25.0% (2 of 8) in patients with serous carcinoma
and with endometrioid carcinoma, respectively. In patients
Table 1. Demographics and baseline characteristics of patients
Characteristics Total (n ¼ 74) Platinum sensitive (n ¼ 11) Platinum resistant (n ¼ 63)
Age, years
Median (range) 57.0 (32–76) 55.0 (40–72) 58.0 (32–76)
Primary cancer (%)
Epithelial ovarian carcinoma 62 (83.8) 11 (100.0) 51 (81.0)
Peritoneal carcinoma 12 (16.2) 0 (0.0) 12 (19.0)
Tumour histology (%)
Serous 49 (66.2) 6 (54.5) 43 (68.3)
Endometrioid 8 (10.8) 3 (27.3) 5 (7.9)
Clear cell 8 (10.8) 1 (9.1) 7 (11.1)
Mucinous 1 (1.4) 0 (0.0) 1 (1.6)
Other 8 (10.8) 1 (9.1) 7 (11.1)
Initial FIGO stage (%)
I 7 (9.5) 1 (9.1) 6 (9.5)
II 1 (1.4) 1 (9.1) 0 (0.0)
III 50 (67.6) 6 (54.5) 44 (69.8)
IV 16 (21.6) 3 (27.3) 13 (20.6)
Previous chemotherapy (%)
1 regimen 23 (31.1) 11 (100.0) 12 (19.0)
2 regimen 50 (67.6) 0 (0.0) 50 (79.4)
3 regimen 1 (1.4) 0 (0.0) 1 (1.6)
Previous chemotherapy with antracycline (%)
Yes 3 (4.1) 0 (0.0) 3 (4.8)
No 71 (95.9) 11 (100.0) 60 (95.2)
Platinum-free interval (days)
Median (range) 263 (28–2792) 315 (216–441) 235 (28–2792)
CA-125 at baseline (U/ml)
Median (range) 243.6 (5.8–7809.8) 192.1 (22.2–808.0) 261.0 (5.8–7809.8)
FIGO, Federation Internationale de Gynecologie et d’Obstetrique.
Table 2. Response rate
Total Platinum sensitive Platinum resistant
Number of patients 73 11 62
Best overall response: n (%)
CR 2 (2.7) 0 (0.0) 2 (3.2)
PR 14 (19.2) 3 (27.3) 11 (17.7)
SD 28 (38.4) 3 (27.3) 25 (40.3)
PD 27 (37.0) 4 (36.4) 23 (37.1)
NE 2 (2.7) 1 (9.1) 1 (1.6)
Response rate
n (%) (95% CI) 16 (21.9) (13.1–33.1) 3 (27.3) (6.0–61.0) 13 (21.0) (11.7–33.2)
CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; NE, not evaluable; 95% CI, conﬁdence interval.
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patients, and the time to progression in the two patients was
350þ and 87þ days, respectively. In patients with mucinous
carcinoma, SD was observed in one of one patient and the
time to progression was 135þ days.
The median and range of the duration of response, time to
response and time to progression are shown in Table 3.
The median time to response (CR or PR) was 54.0 days.
The median time to response was 56.0 days in the platinum-
sensitive group and 52.0 days in the platinum-resistant group.
The median duration of overall response was 149.0 days.
The median duration of overall response in the platinum-
resistant group was 149.0 days, however, that in the
platinum-sensitive group could not be calculated. The
Kaplan–Meier curve for time to progression is shown in
Fig. 1. The median time to progression was 166.0 days:
159.0 days in the platinum-sensitive group and 168.0 days in
the platinum-resistant group. The median survival could not
be calculated.
SAFETY
Adverse drug reactions were reported from all 74 patients
treated with PLD. The major adverse drug reactions observed
in the study are shown in Table 4.
The most common Grade 3 or 4 adverse reactions were
due to haematological toxicity: neutropenia in 50 patients
(67.6%), leukopenia in 44 (52.7%), lymphopenia in 35
(47.3%), decreased haemoglobin in 13 (17.6%), thrombocy-
topenia in ﬁve (6.8%) and erythropenia in three patients
(4.1%). The median time to nadir for neutrophils, WBCs,
haemoglobin and platelets from the start of administration in
the ﬁrst cycle was 21.0 days, 21.0, 15.0 and 22.0 days,
respectively. The median time to recovery to the level at
which the administration of PLD in the next cycle was per-
mitted was 7.0–8.0 days for any haematological event.
Grade 3 or 4 adverse drug reactions due to non-
haematological toxicity included: HFS in 12 patients
(16.2%), stomatitis in six (8.1%), febrile neutropenia,
nausea, ALT (GPT) increased and blood potassium
decreased in two each (2.7%) and deep venous thrombosis
rash, herpes zoster, infection, upper respiratory tract infec-
tion, impaired glucose tolerance, diarrhoea, small intestinal
obstruction, vomiting, fatigue, AST (GOT) increased,
decreased blood sodium and increased g-GTP in one each
(1.4%). Only deep venous thrombosis was Grade 4. The
median time to occurrence of HFS, rash and stomatitis from
the start of administration was 34.0 days (2.0 cycles), 33.0
days (2.0 cycles) and 16.0 days (1.0 cycle), respectively. The
median time to the Grade 2, 3 or 4 adverse reactions (Grade
3 or 4 for rash), which required delay of next administration,
was 64.5 (3.0 cycles), 84.0 (3.0 cycles) and 43.0 (2.0
cycles), respectively and the median duration for those reac-
tions was 15.0, 8.0 and 8.0 days, respectively.
Infusion-related reactions were seen in 14 patients (18.9%)
only during the ﬁrst cycle. Serious reactions were not seen.
Table 3. Time to response, duration of response and time to progression
Total Platinum sensitive Platinum resistant
Number of patients 73 11 62
Time to response (day)
Patient (%)
a 16 (21.9) 3 (27.3) 13 (21.0)
Median (range) 54.0 (20–162) 56.0 (54–59) 52.0 (20–162)
Duration of response (day)
Patient (%)
a 16 (21.9) 3 (27.3) 13 (21.0)
Median (range) 149.0 (56–309) 2 (92–159) 149.0 (56–309)
Withdrawal (%) 11 (68.8) 2 (66.7) 9 (69.2)
Time to progression (day)
Patient (%)
b 71 (97.3) 10 (90.9) 61 (98.4)
Median (range) 166.0 (14–358) 159.0 (16–217) 168.0 (14–358)
Withdrawal (%) 30 (42.3) 4 (40.0) 26 (42.6)
aResponder only.
bExcluded two patients due to unable calculation for time to progression.
Figure 1. Kaplan–Meier estimates of time to progression.
782 Phase II study of the Japanese Gynecologic Oncology GroupOf these patients, one patient had Grade 2 events and other
patients had Grade 1 events. Symptoms associated with
infusion-related reactions included hot ﬂushes, facial ﬂushing
and hot feeling. These symptoms were restored on the day of
occurrence or the following day. PLD was discontinued in
one patient who had nausea, low back pain, chest tightness
and facial ﬂushing as Grade 2 infusion-related reactions.
These symptoms were rapidly restored by supportive care
with drip infusion of physiological saline. Although slow-
down in the PLD infusion rate was required in two patients,
the other 11 patients completed the infusion without any
intervention. Among 14 patients with infusion-related reac-
tions, 11 patients received the next cycle without recurrence
of infusion-related reactions.
Cardiac toxicity was seen in 17 of 74 patients (23.0%), all
of which were Grade 1. Increase in the incidence of cardiac
toxicity associated with accumulation of PLD was not
observed. Alopecia was seen in 18 patients (24.3%), which
was Grade 1 in all of them.
There was no death due to adverse events reported during
the trial period. Fourteen serious adverse reactions were seen
in 11 patients (14.9%): two events each of nausea, HFS,
small intestinal obstruction and stomatitis; and one event
each of neutropenia, leukopenia, vomiting, pneumonitis,
deep venous thrombosis and anorexia.
PLD was discontinued due to adverse reactions in 16
(21.6%). Common adverse reactions that required the discon-
tinuation of PLD included: decreased haemoglobin in six
patients (8.1%), leukopenia in four (5.4%) and HFS and neu-
tropenia in three each (4.1%). The PLD dose was reduced in
24 patients (32.4%) due to adverse drug reactions such as
HFS in 10 patients (13.5%), decreased haemoglobin and sto-
matitis in ﬁve each (6.8%) and neutropenia in three patients
(4.1%). Administration of PLD was delayed in 49 patients
(66.2%) in 111 cycles of 334 cycles due to adverse reactions
mainly including leukopenia in 68 cycles (20.4%), neutropenia
in 56 cycles (16.8%), HFS in 40 cycles (12.0%) and stomatitis
in eight cycles (2.4%).
DISCUSSION
We evaluated the efﬁcacy and safety of PLD in Japanese
patients with Mu ¨llerian carcinoma (epithelial ovarian
carcinoma, primary fallopian tube carcinoma and peritoneal
carcinoma) previously treated with platinum-based
chemotherapy.
Currently, platinum and taxane therapies are used for the
standard ﬁrst-line chemotherapy for treatment of ovarian
carcinoma, though the results of Phase III clinical trials
conducted in the US and Europe demonstrated the effective-
ness of PLD, gemcitabine and topotecan in patients resistant
to these drugs (13,14,20). However, these drugs have not
been approved and the results from prospective studies of
their use in patients with ovarian carcinoma previously
treated with platinum and taxane therapy have not been
reported in Japan. Our study was intended to provide the
outcome in patients who had recurrent Mu ¨llerian carcinoma
after the standard ﬁrst-line chemotherapy (90% of patients in
our study had received ﬁrst-line chemotherapy with platinum
and taxane).
In this trial, the response rate was 21.9% (95% CI: 13.1–
33.1%) for all patients in FAS. The response rate in the
platinum-sensitive and platinum-resistant groups was 27.3%
(95% CI: 6.0–61.0%) and 21.0% (95% CI: 11.7–33.2%),
respectively. Better response was obtained in patients with
longer platinum-free interval when PLD was administered as
second- or third-line chemotherapy. Clinical studies con-
ducted in the US and Europe showed that the response rate
of PLD was 28.4% in the platinum-sensitive group and 6.5–
18.3% in the platinum-resistant group (11,12,13). These
response rates were similar to those obtained in our trial.
Table 4. Grades 3 and 4 adverse drug reactions
Adverse Reaction
(MedDRA/J Ver9.0)
Number of patients (n ¼ 74)
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)
Grade 4
(%)
Neutropenia 8 (10.8) 11 (14.9) 23 (31.1) 27 (36.5)
Lymphocytopenia 15 (20.3) 16 (21.6) 29 (39.2) 6 (8.1)
Leukopenia 5 (6.8) 20 (27.0) 39 (52.7) 5 (6.8)
Haemoglobin decreased 23 (31.1) 27 (36.5) 11 (14.9) 2 (2.7)
Thrombocytopenia 27 (36.5) 13 (17.6) 4 (5.4) 1 (1.4)
Deep vein thrombosis 0 (0) 0 (0) 0 (0) 1 (1.4)
Hand-foot syndrome 20 (27.0) 26 (35.1) 12 (16.2) 0 (0)
Stomatitis 29 (39.2) 22 (29.7) 6 (8.1) 0 (0)
Erythropenia 42 (56.8) 11 (14.9) 3 (4.1) 0 (0)
Nausea 37 (50.0) 6 (8.1) 2 (2.7) 0 (0)
ALT (GPT) increased 16 (21.6) 1 (1.4) 2 (2.7) 0 (0)
Blood potassium
decreased
10 (13.5) 0 (0) 2 (2.7) 0 (0)
Febrile neutropenia 0 (0) 0 (0) 2 (2.7) 0 (0)
Rash 17 (23.0) 19 (25.7) 1 (1.4) 0 (0)
Fatigue 28 (37.8) 5 (6.8) 1 (1.4) 0 (0)
Vomiting 11 (14.9) 5 (6.8) 1 (1.4) 0 (0)
g-GTP increased 13 (17.6) 4 (5.4) 1 (1.4) 0 (0)
Diarrhoea 12 (16.2) 4 (5.4) 1 (1.4) 0 (0)
AST (GOT) increased 18 (24.3) 2 (2.7) 1 (1.4) 0 (0)
Upper respiratory tract
infection
0 (0) 2 (2.7) 1 (1.4) 0 (0)
Blood sodium decreased 15 (20.3) 0 (0) 1 (1.4) 0 (0)
Small intestinal
obstruction
0 (0) 0 (0) 1 (1.4) 0 (0)
Herpes zoster 0 (0) 0 (0) 1 (1.4) 0 (0)
Infection 0 (0) 0 (0) 1 (1.4) 0 (0)
Glucose tolerance
impaired
0 (0) 0 (0) 1 (1.4) 0 (0)
Jpn J Clin Oncol 2008;38(11) 783Common adverse reactions reported in this study were
haematological toxicities (leukopenia, neutropenia and
decreased haemoglobin), HFS and stomatitis.
The median time to nadir for WBC, neutrophils and hae-
moglobin after the start of administration of PLD was 15–22
days, and the median time to recovery to baseline after
reaching the nadir was 7–8 days. Repeated cycles did not
lead to worsening the events. Most patients could receive
PLD continually by concomitant use of G-CSF and dose
modiﬁcation, such as dose reduction and delay of next
administration.
In the previous Phase III study (13), HFS and stomatitis
occurred in 49% (Grade 3 or higher: 23%) and 40% (Grade
3 or higher: 8%) of patients, respectively. Although these
toxicities were seen in 78.3 and 77.0% of patients in our
study, only 16.2 and 8.1% of patients experienced Grade 3
or higher toxicities, respectively. Most patients could conti-
nually receive PLD treatment by dose modiﬁcation of PLD
and supportive care, and the patients discontinued due to
toxicities were few.
Infusion-related reaction that is known as toxicity speciﬁc
to PLD was seen in 14 patients (18.9%) during the ﬁrst cycle,
all of which were resolved on the day of the occurrence or the
following day. The second cycle was administered in 11 of 14
patients with infusion-related reactions. No recurrence of
infusion-related reactions was seen in all 11 patients. It is
important to use PLD with close attention to the condition of
patients at the ﬁrst administration of PLD. Infusion-related
reaction is related to the initial infusion rate of PLD. It has
been reported that decreasing the infusion rate reduces the risk
of the infusion-related reaction (21).
It has been reported that cardiac toxicity, which is a sig-
niﬁcant problem with the use of conventional doxorubicin,
associated with PLD is mild (22). Also in this trial,
all cardiac toxicities observed were Grade 1, and had no
effect on continuation of the trial. Furthermore, no patients
experienced Grade 2 or higher alopecia, and Grade 3 or
higher gastrointestinal toxicities were rarely seen in our trial.
These toxicities are frequently induced by treatment of
conventional doxorubicin.
These results suggest that toxicity of PLD is manageable
by dose modiﬁcation of PLD and supportive care.
Most patients with ovarian carcinoma exhibited response
to ﬁrst-line chemotherapy, however, the incidence of recur-
rence is high and prognosis is poor. It might be important to
recognize that the chemotherapy would be palliative treat-
ment for treatment of recurrent ovarian carcinoma. PLD has
a safety proﬁle that is different from that of platinum and
taxanes, which are used for the standard ﬁrst-line chemother-
apy. PLD has a low risk of enhancing cumulative toxicities
(haematological toxicity or neurotoxicity) associated with
ﬁrst-line chemotherapy. PLD is expected to have a beneﬁcial
effect against disease progression as the proportion of
patients with CR, PR or SD and time to progression were
60.3% and 166 days (median). Furthermore, PLD might
make it easy to provide long-term outpatient chemotherapy
since PLD would reduce a patient burden by dosing once
every 4 weeks.
In conclusion, this trial demonstrated that PLD (50 mg/m
2
every 4 weeks) was expected to have antitumour effect in
Japanese patients with Mu ¨llerian carcinoma previously
treated with platinum-based chemotherapy and that toxicities
associated with PLD are manageable by dose modiﬁcation
and supportive care. In the USA and Europe, combination
chemotherapy with PLD and platinum has recently been
investigated in the platinum-sensitive group where PLD is
considered to be more effective (23,24,25). It is desirable to
investigate the optimal regimen of the combination therapy
in Japan.
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